RAPP vs SNDA: Which Stock Is the Better Buy?
Rapport Therapeutics, Inc. and Sonida Senior Living, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RAPP vs SNDA, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Rapport Therapeutics, Inc. (RAPP) | Sonida Senior Living, Inc. (SNDA) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $0 | $381.14M |
| Net income (latest FY) | $-111.48M | $-70.78M |
| Revenue growth (5y CAGR) | — | -0.1% |
| Net margin | — | -18.6% |
| Return on equity | -23.0% | -138.1% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full RAPP vs SNDA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RAPP's full financials → Open SNDA's full financials →More comparisons
Frequently asked questions
Which is bigger, RAPP or SNDA?
Sonida Senior Living, Inc. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, RAPP or SNDA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.